Table 2.
Behavioral, clinical, biological, and therapy characteristics of the asthma and asthma-suggestive recurrent wheezing patients, reported in relation to Vitamin D status, assessed through the serum 25-hydroxy-vitamin D3 level.
| Question | Suboptimal Serum 25-OH-VitD n = 77 |
Optimal Serum 25-OH-VitD n = 54 |
p Value |
|---|---|---|---|
| Vitamin D3 supplementation in infancy | 83.1% (64/77) | 90.7% (49/54) | 0.21 |
| Vitamin D3 supplementation in the cold season | 75.3% (58/77) | 88.8% (48/54) | 0.052 |
| Parental smoking | 32.4% (25/77) | 37% (20/54) | 0.58 |
| Personal history of atopic dermatitis | 54.5% (42/77) | 61.1% (33/54) | 0.45 |
| Personal history of seasonal allergic rhinitis | 38.5% (22/77) | 14.8% (8/54) | 0.06 |
| Elevated-for-age group serum IgE 1 | 44.1% (34/77) | 57.4% (31/54) | 0.13 |
| Eosinophil count >4% of total white blood count 1 | 31.1% (24/77) | 27.7% (15/54) | 0.23 |
| Hospitalization for asthma attack 2 | 22.0% (17/77) | 11.1% (6/54) | 0.1 |
| Oral corticosteroids for exacerbation therapy 2 | 37.6% (29/77) | 27.7% (15/54) | 0.23 |
| Recent asthma exacerbation 3 | 61.0% (47/77) | 40.7% (22/54) | 0.02 |
1 Assessed at the time of inclusion in the study; 2 Occurred at least once in the last twelve months prior to enrollment in the study; 3 Occurred at least once at any time in the four weeks prior to enrollment in the study.